{
    "clinical_study": {
        "@rank": "20116", 
        "arm_group": {
            "arm_group_label": "IB1001", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety (acute adverse effects associated with infusions, and inhibitor\n      development), pharmacokinetics (PK), and efficacy with respect to breakthrough bleeding and\n      control of hemorrhaging during prophylaxis of IB1001 in subjects with hemophilia B."
        }, 
        "brief_title": "Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hemophilia B", 
        "condition_browse": {
            "mesh_term": [
                "Hemophilia B", 
                "Hemophilia A"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Objectives:\n\n        -  to evaluate safety of IB1001 within the first 50 exposure days,\n\n        -  to determine IB1001 pharmacokinetics (PK), and\n\n        -  to assess efficacy of IB1001 prophylaxis with respect to breakthrough bleeding and with\n           respect to control of hemorrhaging in subjects with severe hemophilia B within the\n           first 50 exposure days\n\n      Secondary Objectives:\n\n        -  to evaluate long-term safety of IB1001; and\n\n        -  to evaluate long term efficacy of IB1001.\n\n      Exploratory Objectives:\n\n        -  to evaluate markers of thrombogenicity during the first 24 hours post-infusion\n           [thrombogenicity markers will include at a minimum D-dimer test; however should there\n           be a clinical reason (e.g., three consecutive elevations in D-dimer levels, a possible\n           clinical thrombogenic episode), sufficient samples will be collected to also evaluate\n           levels of fragment 1+2 (F1+2) and thrombin-antithrombin III complex (TAT)]\n\n        -  to evaluate IB1001 immunogenicity response (development of inhibitory and\n           non-inhibitory factor IX binding antibodies and antibodies to host cell proteins)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age of at least 12 years\n\n          2. Body Mass Index of \u2264 29, with a minimum body weight of 40 kg\n\n          3. Written Institutional Review Board (IRB)/ Ethics Committee (EC)-approved informed\n             consent form (ICF)\n\n          4. Willingness to make the required study visits, and follow instructions while enrolled\n             in the study (up to 12 months)\n\n          5. Severe (factor IX activity \u22642 U/dL) hemophilia B patients with a minimum of 3\n             bleeding episodes over the preceding 6 months or 6 bleeding episodes over the\n             preceding 12 months or in the event the subject is on prophylaxis, a minimum of 3\n             bleeding episodes over the preceding 6 months or 6 bleeding episodes over the\n             preceding 12 months prior to being placed on prophylaxis\n\n          6. Subjects must be on prophylaxis or switch to a prophylaxis regimen for the duration\n             of the PK and Treatment/Continuation Phase of the study\n\n          7. Previously treated patients with a minimum of 150 exposure days to a factor IX\n             preparation\n\n          8. Willingness to adhere to the 5-day washout of any factor IX replacement therapy prior\n             to PK evaluations\n\n          9. Immunocompetent (CD4 count >400/mm3) and not receiving immune modulating or\n             chemotherapeutic agents\n\n         10. Platelet count at least 150,000/mm3\n\n         11. Liver function: alanine transaminase (ALT) and aspartate transaminase (AST) \u22642 times\n             the upper limit of the normal range\n\n         12. Total bilirubin \u22641.5 times the upper limit of the normal range\n\n         13. Renal function: serum creatinine \u22641.25 times the upper limit of the normal range\n\n         14. Hemoglobin \u22657 g/dL at the time of the blood draw\n\n        Exclusion Criteria:\n\n          1. History of factor IX inhibitor \u22650.6 BU (Bethesda units)\n\n          2. Existence of another coagulation disorder\n\n          3. Evidence of thrombotic disease, fibrinolysis or disseminated intravascular\n             coagulation (DIC)\n\n          4. Use of an investigational drug within 30 days prior to study entry\n\n          5. Previous use of IB1001\n\n          6. Use of medications that could impact hemostasis, such as aspirin\n\n          7. Hypersensitivity to the active substance or to any of the excipients in the\n             investigational products\n\n          8. Known allergic reaction to hamster proteins\n\n          9. History of poor compliance, a serious medical or social condition, or any other\n             circumstance that, in the opinion of the investigator, would interfere with\n             participation or compliance with the study protocol\n\n         10. History of adverse reaction to either plasma-derived factor IX or recombinant factor\n             IX that interfered with the subject's ability to treat bleeding episodes with a\n             factor IX product"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02048111", 
            "org_study_id": "IB1001-04"
        }, 
        "intervention": {
            "arm_group_label": "IB1001", 
            "description": "Prophylaxis (during Treatment and Continuation phases): 40 - 75 IU/kg twice weekly.\nThe starting dose for prophylaxis may be based on previous recombinant factor IX product use. The recommended starting prophylaxis dose is 40 - 60 IU/kg twice weekly, however, the investigator may prescribe up to 75 IU/kg twice weekly at their discretion (after clinically assessing the subject) and discretion of the subject.\nThe dose or the frequency of IB1001 prophylaxis may be adjusted at the discretion of the investigator.", 
            "intervention_name": "IB1001", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Hemophilia B", 
            "Hemophilia A", 
            "Blood Coagulation Disorders, Inherited", 
            "Blood Coagulation Disorders", 
            "Hematologic Diseases", 
            "Coagulation Protein Disorders", 
            "Hemorrhagic Disorders", 
            "Genetic Diseases, Inborn", 
            "Genetic Diseases, X-Linked"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients With Severe Hemophilia B", 
        "overall_contact": {
            "email": "fyadao@cangene.com", 
            "last_name": "Fran Yadao, Manager Clinical Operations"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Information on adverse events is collected after each infusion of study drug by a study subject. Assessment of adverse events is then performed by an investigator after 5 infusions of study drug, 1 month, 2 months, 3 months and 6 months of study drug treatment.", 
            "measure": "Number of study subjects with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Within 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02048111"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of bleeding episodes divided by number of months of observation", 
            "safety_issue": "Yes", 
            "time_frame": "Within 12 months"
        }, 
        "source": "Cangene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cangene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}